AlamarBio

[AlamarBio @AlamarBio]

From the promise of eMTBR-tau and multiplex biomarker testing to AI-powered insights, our CSO, Steve Williams, PhD, discusses what's shaping the future of Alzheimer's biomarker research with NeurologyLive at #AAIC2026.

Read the full interview: https://t.co/h91MfxNHdA

[AlamarBio @AlamarBio]

We're pleased to welcome Sequanta Technologies to the Alamar Certified Service Provider network. With #NULISA technology, they're expanding access to ultra-sensitive, high-plex proteomics for biomarker discovery and translational research.

Learn more: https://t.co/VtlZ0b1axD

[AlamarBio @AlamarBio]

This #WorldBrainDay, we're inspired by the progress being made in neuro research. From blood-based biomarkers to deeper insights into disease biology, new technologies are helping researchers expand what's possible in the study of brain health and neurodegenerative disease.

[AlamarBio @AlamarBio]

We're proud to highlight our partnership with Guilford Street Laboratories, an Alamar Biosciences Certified Service Provider (CSP).

Learn more about our CSP program: https://t.co/sOwV1hSNkR

[AlamarBio @AlamarBio]

As blood-based biomarker research advances, the conversation is expanding beyond amyloid alone.

In a recent Healio feature, Alamar CSO Steve Williams discusses blood-based eMTBR-Tau and why measuring both hallmarks of Alzheimer’s disease matters.

🔗: https://t.co/NIFgT9Hjkd

[Longevity Technology @LongevityTech]

New assay could make tracking Alzheimer’s progression easier, bringing precision diagnostics a step closer to everyday research.

https://t.co/C2NKrp7LjM

#longevity #alzheimers #diagnostics #biomarkers #research

@AlamarBio

[AlamarBio @AlamarBio]

Wrapping up an incredible #AAIC2026. From our Product Theater with Dr. Thomas Karikari and Dr. Steve Williams to 140+ scientific presentations featuring #NULISA data, the conversations, collaborations, and science shared this week will continue to inspire what's next.

[AlamarBio @AlamarBio]

Day 3 at #AAIC26 ✅
From last night's networking event, In Navis Veritas, aboard the Cutty Sark, to today's Beyond pTau217 product theater, the last 24 hours have been packed with great discussions and new insights on Alzheimer's research.
#Alzheimers #PrecisionProteomics

[AlamarBio @AlamarBio]

At #AAIC2026, one message is clear: Alzheimer's disease can't be understood with a single biomarker.
Alamar CSO Steve Williams shares why multiplex biomarker profiling and blood-based testing are becoming critical for disease staging, clinical trials, and precision medicine.

[AlamarBio @AlamarBio]

AAIC Day 2 ✅
More great science, more great conversations. Excited to see growing momentum around blood-based biomarkers and proteomics in Alzheimer's research.
Visit us at Booth 530 and please join our Product Theater on Tuesday, July 14, 1:20-2:00pm!
#AAIC26 #Alzheimers

[AlamarBio @AlamarBio]

Alamar is partnering with Washington University, University of Wisconsin, and Indiana University to create a national proteomics resource for ADRD research. Profiling ~21,000 plasma samples from 10,000 participants. Read more: https://t.co/WbFSx6IfNz

[AlamarBio @AlamarBio]

AAIC Day 1 ✅
The highlight? The conversations. Thanks to the researchers, collaborators, and new connections who stopped by Booth 530 today. We're excited to see the momentum behind proteomics in Alzheimer's research.
#AAIC26 #Alzheimers

[AlamarBio @AlamarBio]

We’re proud to welcome Bredis Healthcare as our newest CSP! Bredis delivers ultrasensitive immunoassay and proteomics services under GCLP and ICH standards in a dedicated cleanroom laboratory to advance biomarker research.

Explore our CSPs: https://t.co/xADvk84HVy

[AlamarBio @AlamarBio]

🎉 Another FIRST for Alamar! We've launched the first commercial multiplexed immunoassay for eMTBR-Tau. Available in the NULISAseq™ Neuro 220 Panel and through TAP. See the data at AAIC 2026 in London, July 14.

Read the release: https://t.co/reNo1k0eN0

[AlamarBio @AlamarBio]

A warm welcome to our Summer 2026 Interns! 🌟 We're excited to have you join us for a summer of innovation, collaboration, and growth. We can't wait to see the impact you'll make as we advance precision proteomics. Welcome to the team!

[AlamarBio @AlamarBio]

Join Alamar Biosciences at #AAIC26! Visit Booth 530 to see how ultra-sensitive precision proteomics is advancing biomarker discovery and translational research in Alzheimer's and other neurodegenerative diseases.

👉 Learn more: https://t.co/0YTYe7HsXo

[AlamarBio @AlamarBio]

We're excited to be at the Singapore Neuroscience Association Meeting as a Platinum Sponsor. Join Caroline Chan, PhD, as she presents how NULISA enables automated, ultra-sensitive biomarker profiling from biofluid samples. Thank you to Genomax Technologies for their partnership.

[AlamarBio @AlamarBio]

Join us at T21RS as Charlie Grieser, VP, Business Development – Population Health at Alamar, presents how ultra-sensitive biomarker profiling is providing new insights into AD progression and neuroinflammatory changes in Down syndrome.

👉: https://t.co/mTc0H8JO3c

[AlamarBio @AlamarBio]

Big news! Paris Brain&Mind is now the first European Center of Excellence for Alamar Biosciences.

Together, we're accelerating the future of clinical proteomics through early access to next-gen NULISA assays, NULISA expert centers, and emerging bioinformatics pipelines.

[AlamarBio @AlamarBio]

This June, we recognize Alzheimer’s & Brain Health Awareness Month. At Alamar Biosciences, we empower researchers with ultra-sensitive proteomics like NULISA™ to advance biomarker discovery and deepen our understanding of neurodegenerative disease.

#EndAlz #PrecisionProteomics